|
The Role of Gnrh Analogues in 36-Month Disease-Free Survival in Non-Menopausal Patients with Hormone Receptor-Positive
Breast Cancer
|
S Akbarzadeh Pasha    , A Gholizadeh Pasha , M Raanaee , A Moghadamnia , A Vallard , D Moslemi * |
| 4. Department of Radiation Oncology, School of Medicine, Babol University of Medical Sciences, Babol, I.R.Iran , moslemi_d@yahoo.com |
|
|
Abstract: (2304 Views) |
BACKGROUND AND OBJECTIVE: The effectiveness of ovarian function suppression therapies in patients with non-menopausal breast cancer has not yet been established. This study was performed to evaluate the role of gonadotropin-releasing hormone agonist (GnRH agonist) receptor in reducing local recurrence or metastasis in non-menopausal women with localized breast cancer.
METHODS: This clinical trial was performed on 104 non-menopausal women with localized and advanced localized breast cancer (in stages 2 and 3) with positive hormone receptor (HR+) in the two groups of control and intervention with GnRH analog. The control group received standard treatment at the time of the study, which included tamoxifen. The GnRHa group received 3.75 mg triptorelin subcutaneously per month in addition to the standard treatment. Patients were evaluated for local recurrence and metastasis within 36 months.
FINDINGS: The mean age of patients was 39.78±3.99 years. 9 patients in the control group (mean metastasis time of 17±6.65 months) and 6 patients in the GnRHa group (mean metastasis time of 14.33±8.12 months) had metastasis (p=0.498). The 36-month disease-free survival was 83.3% in the control group and 88% in the GnRHa group (p=0.518). 36-month disease-free survival in patients with HER2, 1+ or higher levels was greater in the GnRHa group compared to controls (p=0.049). In patients who received GnRH analogues, patients with HER2/neu 1+ and above had 20.7% less metastasis than patients with HER2 0 (p=0.029). However, this significant difference was not seen in the control group and other variables.
CONCLUSION: According to the results of this study, GnRH analogues do not have a significant effect on reducing the rate of metastasis in patients who received it compared to other patients in a short-term period. |
|
| Keywords: Breast Neoplasm, Triptorelin, Gonadotropin-Releasing Hormone (Gnrh), Erbb-2 Receptor. |
|
|
Full-Text [PDF 392 kb]
(849 Downloads)
|
Type of Study: Case-Control |
Subject:
Pharmacology
Received: 2020/06/28 | Accepted: 2020/09/15 | Published: 2020/11/7
|
|
|
|
|
|
|
| Send email to the article author |
|
|
